A pooled analysis of two phase I studies on RC48-ADC (NCT02881138 and NCT03052634) have shown increasing response in terms of tumour shrinkage and PFS at higher doses, achieving an ORR of 40.0% (95% CI: 21.1, 61.3) and PFS of 6.3 months (95% CI: 4.3, 8.8) with a dose of 2.5 mg/kg in pre-treated HER2-postive BC (Wang et al., 2018). The gene discussed is ERBB2; the disease is breast cancer.